ESMO22: resequencing melanoma treatment can lower rates of recurrence

A Phase II clinical trial (SWOG S1801) has revealed that in cases of resected Stage III–IV melanoma, an improvement in event-free survival can be achieved by administering immunotherapy treatment in a different order. The results of this randomized Phase II SWOG S1801 trial were presented for the first time at the ESMO Congress 2022 (9–13 September, Paris, France). Adjuvant treatment in the form of anti-PD-1 or targeted therapy is currently considered for select high-risk patients of melanoma. When compared to adjuvant therapy (AT), neoadjuvant therapy (NAT) is thought to elicit a higher immune response against in vivo tumor antigens. However,...